Related Experiment Video
Updated: Aug 16, 2026

Porcine As a Training Module for Head and Neck Microvascular Reconstruction
Published on: September 29, 2018
Pamicogrel (Kanebo)
1Department of Pharmacology and Therapeutics, University of Calgary, 3330 Hospital Drive, Alberta, Canada. plight@acs.ucalgary.ca
Abstract:
Pamicogrel is a cyclooxygenase inhibitor with platelet anti-aggregatory properties which is under development by Kanebo for chronic arterial occlusion. It also has potential in both prophylaxis and treatment of ischemic brain injury. An NDA was submitted in Japan in April 1997. The effects of the drug on platelet aggregation were originally disclosed in EP-00159677, while the later European patent, EP-00560136, claims its use in brain dysfunction induced by hypoxia arising from disturbance of cerebral circulation, such as cerebral hemorrhage or cerebral infarction.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acute Coronary Syndrome IV: Interprofessional Care
Pulmonary Embolism I: Introduction
Pulmonary Embolism I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome V: Nursing Management
